Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Non-Current Deferred Tax Liability (2020 - 2025)

Maravai Lifesciences Holdings has reported Non-Current Deferred Tax Liability over the past 5 years, most recently at $2.0 million for Q2 2025.

  • Quarterly results put Non-Current Deferred Tax Liability at $2.0 million for Q2 2025, changed N/A from a year ago — trailing twelve months through Jun 2025 was $2.0 million (changed N/A YoY), and the annual figure for FY2024 was $11000.0, changed.
  • Non-Current Deferred Tax Liability for Q2 2025 was $2.0 million at Maravai Lifesciences Holdings, up from $2.0 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for MRVI hit a ceiling of $8.7 million in Q1 2023 and a floor of $11000.0 in Q4 2024.
  • Median Non-Current Deferred Tax Liability over the past 4 years was $6.7 million (2023), compared with a mean of $5.2 million.